

EMA/584833/2018

European Medicines Agency decision

P/0280/2018

of 12 September 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ivosidenib (EMA-002247-PIP03-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0280/2018

of 12 September 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ivosidenib (EMA-002247-PIP03-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Agios Pharmaceuticals, Inc. on 23 November 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 July 2018, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ivosidenib, film-coated tablet, age-appropriate solid dosage form, oral use, nasogastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ivosidenib, film-coated tablet, age-appropriate solid dosage form, oral use, nasogastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for ivosidenib, film-coated tablet, age-appropriate solid dosage form, oral use, nasogastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Agios Pharmaceuticals, Inc., 88 Sidney Street, 02139-4169 - Cambridge (Massachusetts), United States.

EMA/PDCO/302105/2018

London, 27 July 2018

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002247-PIP03-17

Scope of the application

Active substance(s):

Ivosidenib

Condition(s):

Treatment of acute myeloid leukaemia

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate solid dosage form

Route(s) of administration:

Oral use

Nasogastric use

Name / corporate name of the PIP applicant:

Agios Pharmaceuticals, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Agios Pharmaceuticals, Inc. submitted for agreement to the European Medicines Agency on 23 November 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 3 January 2018.

Supplementary information was provided by the applicant on 4 May 2018. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of acute myeloid leukaemia

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- film-coated tablet, oral use, age-appropriate solid dosage form, oral use, nasogastric use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Treatment of acute myeloid leukaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients from 2 to less than 18 years of age with newly diagnosed or relapsed or refractory acute myeloid leukaemia with an isocitrate dehydrogenase-1 mutation

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate solid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate formulation, adapted from the ivosidenib tablets 250 mg (film-coated) and ivosidenib tablets 50 mg to generate an oral suspension.
Non-clinical studies	0	Not applicable.

Clinical studies	1	Study 2 Open-label, single-arm, multi-centre, 2-cohort trial to evaluate the safety, pharmacokinetic and anti-tumour activity of ivosidenib, used in monotherapy in paediatric patients from 2 to less than 18 years of age with relapsed or refractory acute myeloid leukaemia with an isocitrate dehydrogenase 1 mutation (Cohort 1), or in combination with chemotherapy in paediatric patients from 2 to less than 18 years of age with newly-diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase 1 mutation (Cohort 2).
Extrapolation, modelling and simulation studies	2	Study 3 Modelling and simulation study to evaluate the relationship between exposure and safety of ivosidenib in paediatric patients from 2 to less than 18 years of age with relapsed/or refractory or newly-diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase 1 mutation. Study 4 Extrapolation analysis based on PK and exposure-response modelling/simulation to evaluate the relationship between exposure and response of ivosidenib in paediatric patients from 2 to less than 18 years of age with relapsed or refractory or newly-diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase 1 mutation.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes